Genetics and current treatment strategy of colorectal cancer

  • Authors

    • Muhammad Islam Post-Graduate Program in Pharmaceutical Science, Federal University of Piaui, Teresina (PI)- 64.049-550.
    2017-08-20
    https://doi.org/10.14419/ijm.v5i2.8078
  • Colorectal Cancer, Present Scenario, Medical Science.

  • Abstract

    This review aims to sketch a current scenario of colorectal cancer (CRC). Findings say that males are the most susceptible to CRC than the females. BRAF and RAS mutations are known as common causes of CRC. Not only targeted therapy but also a combination of radio- and chemotherapy is very useful in CRC.

  • References

    1. [1] Adam R, Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, The C, Tejpar S, Cutsem EV, Vauthey J-N, PÃ¥hlman L. 2015. Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus. Cancer Treatment Rev. 41(2015):729-741. https://doi.org/10.1016/j.ctrv.2015.06.006.

      [2] Ahn TS, et al. 2014. The BRAF mutation is associated with the prognosis incolorectal cancer. J. Cancer Res. Clin. Oncol. 140:1863-1871. https://doi.org/10.1007/s00432-014-1735-y.

      [3] Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, Deraco M. 2016. Progress in treatments for colorectal cancer peritoneal metastasesduring the years 2010–2015. A systematic review. Critic. Rev. Oncol. /Hematol. 100(2016):209-222. https://doi.org/10.1016/j.critrevonc.2016.01.017.

      [4] Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P. 2010. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol. Assessment 14(32):1-206. https://doi.org/10.3310/hta14320.

      [5] Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. 2010. Colorectal cancer. Lancet 375(9719):1030-1047. https://doi.org/10.1016/S0140-6736(10)60353-4.

      [6] Doyle VC, Logullo Waitzberg, AG, Kiss, DR, Waitzberg, DL, Habr-Gama, A, Gama-Rodrigues, J. 2007. Nutrition and colorectal cancer risk: a literature review. Gastroenterol. Nursing 30(3):178-182. https://doi.org/10.1097/01.SGA.0000278165.05435.c0.

      [7] Fitzpatrick-Lewis D, Ali MU, Warren R, Kenny M, Sherifali D, Paina P. 2016. Screening for Colorectal Cancer: A Systematic Review and Meta-Analysis. Clin. Colorectal Cancer 2016. https://doi.org/10.1016/j.clcc.2016.03.003.

      [8] Giampieri R, Caporale M, Pietrantonio F, De Braud F, Negri FV, Giuliani F, Pusceddu V, Demurtas L, Restivo A, Fontanella C, Aprile G, Cascinu S, Scartozzi M. 2016. Second-line angiogenesis inhibition in metastatic colorectal cancerpatients: Straightforward or overcrowded? Critic. Rev. Oncol./Hematol. 100(2016):99-106. https://doi.org/10.1016/j.critrevonc.2016.02.005.

      [9] Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. 2011. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J. Clin. Oncol. 29(28):3775-3782. https://doi.org/10.1200/JCO.2011.35.7566.

      [10] National Cancer Institute (NCI). 2014. General Information about Colon Cancer. 2014-05-12. Retrieved 29 June 2014.

      [11] Ng HJ, Aly EH. 2013. Vaginal metastases from colorectal cancer. Int. J. Surgery 11(2013):1048-1055. https://doi.org/10.1016/j.ijsu.2013.09.004.

      [12] Passiglia F, Bronte G, Bazan V, Galvano A, Vincenzi B, Russo A. 2016. Can KRAS and BRAF mutations limit the benefit of liver resection inmetastatic colorectal cancer patients? A systematic review andmeta-analysis. Critic. Rev. Oncol./Hematol. 99(2016):150-157. https://doi.org/10.1016/j.critrevonc.2015.12.015.

      [13] Serrablo A, Paliogiannis P, Pulighe F, Saudi-Moro Moro S, Borrego-Estella V, Attene F, Scognamillo F, Horndler C. 2016. Impact of novel histopathological factors on the outcomes of liver surgery for colorectal cancer metastases. EJSO xx (2016):1-10. https://doi.org/10.1016/j.ejso.2016.02.013.

      [14] Siravegna G, Bardelli A. 2016. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. Molecular Oncol. 10: 475-480. https://doi.org/10.1016/j.molonc.2015.12.005.

      [15] Sunakawa Y, Bekaii-Saab T, Stintzing S. 2016. Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. Cancer Treatment Rev. 45(2016):97-104. https://doi.org/10.1016/j.ctrv.2016.03.007.

      [16] World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.5. ISBN 9283204298.

      [17] World Health Organization. Cancer. Fact sheet 297. February 2015. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed: April 18, 2016.

      [18] Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. 2011. Meta-analysis: Serum vitamin D and colorectal adenoma risk. Preventive Med. 53(1-2):10-16. https://doi.org/10.1016/j.ypmed.2011.05.013.

      [19] Yörüker EE, Holdenrieder S, Gezer U. 2016. Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer. Clin. Chim. Acta 455(2016):26-32. https://doi.org/10.1016/j.cca.2016.01.016.

  • Downloads

  • How to Cite

    Islam, M. (2017). Genetics and current treatment strategy of colorectal cancer. International Journal of Medicine, 5(2), 226-227. https://doi.org/10.14419/ijm.v5i2.8078

    Received date: 2017-07-04

    Accepted date: 2017-08-07

    Published date: 2017-08-20